COSCIENS Biopharma Inc
TSX:CSCI
CSCI's latest stock split occurred on May 3, 2024
The company executed a 1-for-4 stock split, meaning that for every 4 shares held, investors received 1 new share.
Before the split, CSCI traded at 2.76 per share. Afterward, the share price was about 10.79.
The adjusted shares began trading on May 3, 2024. This was CSCI's 4th stock split, following the previous one in Jul 21, 2022.
688788
COSCIENS Biopharma Inc
Glance View
COSCIENS Biopharma Inc is a CA-based company operating in Biotechnology industry. The company is headquartered in Toronto, Ontario. COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The firm is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
You don't have any saved screeners yet